Cambridge-based CuspAI raises £302.8m backed by Bezos Expeditions and Kleiner Perkins
This article covers Cambridge biotech startup CuspAI, which has closed a growth funding round of £302.8m. The funding supports the startup's generative AI work in materials discovery and targets industrial applications, investors and the UK deeptech and startup ecosystem.
Cambridge biotech startup CuspAI has closed a growth funding round of £302.8m, a raise that takes its total fundraising to more than £378.5m and — according to media reports — could value the company at roughly £2bn. The size of the cheque and the report of high-profile backers mark the company as one of the most capitalised ventures to emerge from Cambridge in recent years.
Why it matters
The scale of this round, if confirmed, signals growing investor appetite for companies applying generative AI to materials discovery. CuspAI’s fundraise would make it one of the best-funded Cambridge startups on record and underline a broader shift: deep learning techniques are moving out of purely software domains and into physical sciences, where speed and manufacturability are essential.
The reported jump in valuation from roughly £394m last year to around £2bn also highlights how capital markets are re-pricing frontier AI plays that can show industrial partnerships and pathways to manufacturable outputs.
Inside the product
CuspAI bills itself as a “search engine for the material world.” Its platform lets users specify desired properties — strength, conductivity, thermal tolerance — and returns candidate chemical compositions. The company says its synthesis-aware generative AI models prioritise designs that can actually be manufactured rather than only simulated, and that its approach can produce suggestions up to ten times faster than traditional methods.
That emphasis on manufacturability is important. Materials discovery that cannot be synthesised has limited commercial value, so the company’s focus on synthesis-aware models is a direct response to a common bottleneck in materials research.
Partners named by the company include Meta, Hyundai and Kemira. Each relationship points to a concrete use case: Meta for carbon-capture materials, Hyundai for sustainable energy applications, and Kemira for removing PFAS compounds from water — examples that show how materials discovery has near-term industrial relevance across sectors.
Who are the investors?
Reports say the latest round is being backed by Jeff Bezos’s family office, Bezos Expeditions, alongside US venture firm Kleiner Perkins. Earlier this time last year CuspAI raised around £75.7m from investors in Singapore and the US, and the new raise would bring its total funding to more than £378.5m.
Bezos Expeditions is the personal investment vehicle of Jeff Bezos. Media coverage has linked Bezos to previous large-scale investments in the Cambridge cluster, including the heavily reported backing of Altos Labs, a California-headquartered anti-ageing company with facilities near Cambridge. Kleiner Perkins is a long-established Silicon Valley venture firm with a history of backing deeptech and biotech companies.
The investor line-up and the reported valuation reflect a convergence of capital from family offices and prominent venture firms into firms applying AI to hard-science problems. The deal therefore sits at the intersection of biotech, materials science and frontier AI — a combination that has attracted renewed interest from institutional and private investors in recent years.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
CuspAI was founded in 2024 by Dr Chad Edwards and Professor Max Welling. Dr Edwards, chief executive and co-founder, is a chemist and DeepTech entrepreneur who previously helped grow quantum computing company Quantinuum. Professor Welling is a Dutch computer scientist who has held senior research roles at Microsoft Research and Qualcomm.
The founders’ backgrounds combine domain expertise in chemistry and advanced machine learning, a pairing that is increasingly common among startups attempting to close the gap between algorithmic discovery and real-world manufacturing.
The bigger picture
The CuspAI story sits within two parallel trends in the UK and European ecosystem. First, the pipeline of startups using AI to tackle physical sciences problems — from drug discovery to novel materials — has expanded rapidly, attracting larger cheques and higher valuations. Second, Cambridge continues to export high-profile ventures that draw international capital, reinforcing its role as a European deeptech hub.
If the reported investor interest and valuation hold, the round will be another data point showing how biotech and deeptech investors are moving beyond early-stage bets into much larger, growth-oriented financings for companies that can demonstrate industrial partnerships and tangible routes to manufacturing.
The deal will be watched by policymakers and investors alike as part of broader questions about how Europe retains and scales companies at the intersection of AI and the physical sciences.
They've invested in CuspAI
Get to know these biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Kleiner Perkins( ) Menlo Park, US  | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK